My Top 10 Stocks to Buy for 2026

Together, these stocks offer you a balanced mix of growth and safety. These companies span a number of industries, and many are leaders in their markets.

The Motley Fool • a day ago

Investment strategist names 10 sub-$10 billion stocks to watch in 2026

Investment strategist Shay Boloor has outlined ten sub-$10 billion market-cap companies he believes are positioned to benefit from powerful long-term trends heading into 2026.

Finbold • 13 hours ago

3 Underrated Growth Stocks That Look Like Great Buys Heading Into 2026

The best-performing stock on this list is up just 4% this year. Investors may be undervaluing these companies' growth opportunities.

The Motley Fool • Dec 11, 2025

Viking Therapeutics: Prepping For A Critical 2026

Viking Therapeutics is positioned for a pivotal 2026, advancing both injectable and oral VK2735 in obesity, with pipeline depth from an emerging amylin agonist program. VKTX's oral VK2735 has demonstrated unmatched double-digit weight loss in 13 weeks, potentially establishing leadership in the oral obesity drug segment. Despite a robust $714M cash position and a 4/5 conviction rating, risks include Phase III trial costs, competitive pressures, and potential dilution.

Seeking Alpha • Dec 6, 2025

Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics

Biotech stocks and research shares diverged Thursday after reports suggested the FDA will soon require just one pivotal study.

Investors Business Daily • Dec 4, 2025

VKTX Stock Rises 34% in Three Months: Here's What You Should Know

Viking Therapeutics' shares jump 34% as rapid VK2735 trial enrollment boosts optimism amid intensifying interest in obesity treatments.

Zacks Investment Research • Dec 1, 2025

Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zacks Investment Research • Nov 28, 2025

Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029

Viking Therapeutics could enter the weight loss market by 2029. The company's leading candidate looks very promising.

The Motley Fool • Nov 27, 2025

Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference

SAN DIEGO , Nov. 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the Piper Sandler 37th Annual Healthcare Conference. The conference will take place December 2-4, 2025, in New York, New York.

PRNewsWire • Nov 25, 2025

2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon

If you want to invest in top healthcare stocks, both of these are worth consideration. Pfizer is moving past the pandemic era, and tremendous growth could be ahead.

The Motley Fool • Nov 22, 2025